Apremilast (Otezla) for psoriasis

Apremilast (brand name Otezla) is an oral medicine taken as a pill, not an injection or infusion like most biologics. It is a phosphodiesterase-4 (PDE4) inhibitor: it raises a molecule called cAMP inside immune cells, which lowers several inflammatory signals involved in psoriasis. The exact way it controls psoriasis is not fully understood. Unlike methotrexate or cyclosporine, it does not require routine blood tests while you take it.⌁ Evidence⌁ Evidence⌁ Evidence

The current label approves apremilast for adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, at any severity level. It is also approved for children six and older who meet weight and severity criteria, for psoriatic arthritis, and for the mouth ulcers of Behçet’s disease. National Psoriasis Foundation patient education states apremilast has been shown to be safe and effective when combined with methotrexate. It can also be combined with phototherapy or topical treatments. The label advises against combining it with strong CYP3A4-inducing medicines, such as rifampin, because they can substantially reduce how well apremilast works. If you have severe kidney impairment, the maintenance dose is reduced.⌁ Evidence⌁ Evidence

Apremilast starts with a five-day dose increase, called titration, beginning at 10 mg in the morning on day 1. It reaches the full maintenance dose of 30 mg twice daily by day 6. An extended-release version, Otezla XR, is taken as one 75 mg tablet once daily after the same titration. You can take it with or without food, and you need to keep taking it to keep its effect. In clinical trials for plaque psoriasis, about 20% of patients were clear or almost clear by week 16, and about a third saw 75% or greater improvement. Itch, nail psoriasis, and scalp psoriasis also improved for many patients by week 16.⌁ Evidence⌁ Evidence

Apremilast carries no boxed warning, but it does carry several warnings worth knowing. It can increase the risk of depression; the label advises watching for new or worsening depression, suicidal thoughts, or other mood changes. It can also cause weight loss: in trials, 10 to 12% of adults lost 5 to 10% of their body weight, so your dermatologist should monitor your weight regularly. The most common side effects in plaque-psoriasis trials were diarrhea and nausea (17% each), upper-respiratory infection (9%), and headache (6%), most within the first few weeks. If diarrhea, nausea, or vomiting become severe, your dermatologist may lower your dose or pause treatment.⌁ Evidence

People I have heard from ask first whether they can afford this at all. Otezla has no generic version on the market yet: a generic has FDA approval, but patent litigation is expected to delay its launch until 2028 or 2029. I looked at one pharmacy-price snapshot. It showed an average retail cash price of roughly $6,965 to $7,117 for 60 tablets of Otezla 30 mg, with a GoodRx-coupon price around $3,354. Amgen’s own Otezla Co-Pay Program states eligible patients with commercial insurance can pay as little as $0 a month. It excludes anyone on Medicare, Medicaid, or another government-funded plan. Uninsured or underinsured patients who qualify can be connected to the Amgen Safety Net Foundation for free medicine.⌁ Evidence⌁ Evidence

No reader has sent me a first-hand account of apremilast for psoriasis yet. Until someone does, here is what the label and the studies say about living with it.⌁ Evidence

Keep a dated record of each titration dose during the first five days, since missing a step can make GI side effects worse. Track your weight regularly, and note any mood changes, since both are things the label asks your dermatologist to monitor. Track diarrhea, nausea, or vomiting, especially in the first few weeks, since severe symptoms may call for a lower dose. Add a same-conditions photo around the sixteen-week mark, matching the trial timeline patient-education sources describe.⌁ Evidence⌁ Evidence